BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 24, 2015 8:16 am | News | Comments
Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
Pharmaceutical companies sponsoring clinical trials showed strong improvement in their...
The drug, liraglutide, will be marketed under the brand name Saxenda. It is approved for obese...
Novo Nordisk has announced plans to hire up to 90 people at its newly-acquired manufacturing...
Under the terms of the contract, Jacobs is providing engineering, procurement and construction management services for a new purification pilot plant project, which initially involves one purification line. The project is expected to expand Novo Nordisk’s capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs in development.
Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity. The panel of Food and Drug Administration advisers voted 14-1 that the injectable drug's benefits outweigh it risks for patients who are obese or dangerously overweight.
The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
Novo Nordisk announced the availability of its newest prefilled insulin delivery device Levemir® FlexTouch® (insulin detemir [rDNA origin] injection) in the United States.
Lilly said that a once-weekly, 1.5-milligram dose of dulaglutide was not inferior to a daily, 1.8 milligram dose of Novo Nordisk's Victoza in a study of nearly 600 patients who were already taking metformin, an older diabetes treatment.
Novo Nordisk is recalling 3 million insulin products used for diabetes treatment in 13 European countries due to a production problem that can affect the strength of the drug. The Danish drug maker says Friday's recall affects certain batches of the prefilled insulin pen NovoMix30 FlexPen.
The European Medicines Agency said Friday it uncovered no new evidence of pancreas-related safety issues after reviewing a group of recently approved diabetes drugs. The agency's Committee for Medicinal Products for Human Use reviewed the safety of so-called GLP-1 diabetes therapies after a study...
Novo Nordisk said it and Deen have "mutually agreed to suspend our patient education activities for now." Deen, who specializes in Southern comfort food, had been promoting the company's drug Victoza since last year when she announced she had Type 2 diabetes.
The Wall Street Journal discusses the Food Network’s decision to drop Paula Dean over racial slurs she made in the past. Novo Nordisk, which uses the cooking show host to promote a diabetes drug could be the next big sponsor to drop her over the controversy
Dr. Peter C. Butler initially declined a request by the drugmaker Merck to test whether its new diabetes drug, Januvia, could help stave off the disease in rats. “I said, I’m not interested in your money, go away,” Butler recalled. Merck no doubt now wishes it had.
Novo Nordisk announced Wednesday that first-quarter profit jumped 28 percent versus the year-ago period to 6 billion Danish kroner ($1.1 billion), boosted by higher sales of insulins and Victoza, beating analyst estimates of 5.8 billion kroner ($1 billion).
Novo Nordisk today unveiled its new U.S. headquarters. Located in Mercer County in Plainsboro, N.J., the world-class building is the result of a $225 million redevelopment project, which utilized an existing structure and sustainable materials to limit environmental impact.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
Shares of Novo Nordisk are sinking in premarket trading after the Danish drugmaker said U.S. regulators want more data before they can finish their review of two long-acting insulin drugs to treat diabetes. The company said Sunday the Food and Drug Administration requested information from a study that looks at cardiovascular health before it can finish reviewing Tresiba and Ryzodeg
Danish pharmaceutical company Novo Nordisk A/S has reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide approved its latest range of insulin products.
Shares of Novo Nordisk plunged after U.S. drug regulators raised safety questions about the company's experimental long-acting insulin for patients with diabetes.
COPENHAGEN, Denmark (AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 35 percent in the third quarter of 2012, chiefly spurred by strong sales of its diabetes drugs.
NEW YORK (AP) — A Jefferies & Co. analyst said Thursday that sales of diabetes drugs should keep growing at a strong clip for the rest of the decade, reaching $65 billion a year in 2020.
COPENHAGEN, Denmark (AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.
Novo Nordisk announced today that the FDA has approved Levemir (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes.
Novo Nordisk Inc., a global healthcare company with 89 years of innovation and leadership in diabetes care, announced today that Robert Clark will be joining the company's U.S. business as Vice President, Regulatory Affairs starting May 14.
Novo Nordisk Inc. today announced plans for a nearly 15 percent expansion of its U.S. work force in 2012. Novo Nordisk has experienced solid growth over the past five years, with an approximately 10 percent increase in U.S. staff per year across a number of specialties. Recruiting is expected to start immediately.
Yesterday, Public Citizen, a US-based consumer advocacy organization filed a petition calling on the FDA to remove Novo Nordisk’s diabetes medicine Victoza® from the US market.In response, Novo Nordisk‘s US affiliate, Novo Nordisk Inc, issued the following statement
WASHINGTON (AP) — A consumer advocacy group is calling on government regulators to withdraw a diabetes drug from Novo Nordisk, saying the injectable medication raises the risk of thyroid cancer, pancreatitis and kidney failure.
Sun Pharmaceutical Industries Ltd. announced that the United States Supreme Court has ruled in favour of its subsidiary Caraco Pharmaceutical Laboratories, Ltd. in its' patent litigation against Novo Nordisk over Caraco's generic version of Prandin, Repaglinide Tablets.
- Page 1